molmir raises JPY300m Series A for drug-discovery programmes
The financing supports molecular-dynamics research, pipeline development and pharmaceutical partnerships.
molmir Inc. has raised JPY300 million in a Series A equity financing announced on April 22. Participants include UntroD Capital Japan, Mitsubishi UFJ Capital, Senshu Ikeda Capital, BP Capital, Nanto Capital Partners and Higin Capital.
The company will advance TDP-43 drug research for ALS, expand its molecular-dynamics platform and develop antibody and diagnostic programmes for acquired von Willebrand syndrome. It also plans to strengthen pharmaceutical partnerships and its research and business-development teams.
molmir uses CHEmir and MAGmir to study molecular behaviour. Its AVWS programme was preparing for an investigator-initiated Phase I trial at the time of the announcement.
Use of funds
Advance TDP-43 drug research and molecular-dynamics platform
Develop AVWS antibody and diagnostic programmes
Expand pharmaceutical partnerships and R&D capacity